DelveInsight

DelveInsight, a prominent business consulting and market research firm, distinguishes itself by seamlessly merging industry expertise with insightful market analysis methodologies to furnish crucial insights to top-tier decision-makers. The organization's mission centers around assisting its clientele in the acquisition of pertinent information, thereby enhancing their decision-making capabilities. DelveInsight is adept at recognizing potential market opportunities, conducting competitor assessments, and undertaking comprehensive evaluations of the business environment. Notably, DelveInsight serves as a trusted and informed partner, offering invaluable support in shaping business strategies and conducting market research across the entire drug value chain.

DelveInsight's primary conduit for delivering intelligent information to professionals in both the business and healthcare sectors is through its meticulously crafted analytical and strategic reports. Presently, DelveInsight boasts a diverse portfolio encompassing over 3,000 Marketed and Pipeline Reports. These reports are thoughtfully categorized based on parameters such as indication, mechanism of actions, drugs, global API manufacturers, and specialized reports focusing on pivotal areas such as Onco-Immunology, Orphan Diseases, Biologics & Biosimilars, Gene Therapy, Stem Cells Therapy, and other emerging domains. This robust platform has become the go-to resource for numerous enterprises seeking to transform and redefine their business strategies.

DelveInsight's offerings extend beyond reports to encompass Consulting Projects and Competitive Intelligence services, catering to the multifaceted needs of its clientele. Moreover, the organization is dedicated to providing tailor-made research services that align with the specific interests and requirements of its clients. DelveInsight's commitment to excellence and innovation positions it as a trusted partner in the areas of business strategy and market research.

View recent articles by this publisher on our blog:
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
The Power of Digital Therapeutics in Mental Health
Anti-VEGF Therapies: Forever Market Rulers of Wet-AMD Treatment?
Additional articles from this publisher

...Show More ...Show Less

8,751 Reports from DelveInsight

Sort by:

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 Key Highlights In 2023, the total market size of CHF was around USD 8,000 million in the 7MM—the increasing prevalence of the disease is expected to fuel the market during 2020–2034. The prevalence of heart ... Read More
Pemphigus Vulgaris (PV) - Market Insight, Epidemiology And Market Forecast - 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

Pemphigus Vulgaris (PV) - Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in t ... Read More
Dementia Associated With Alzheimer’s Disease - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 3,000

Dementia Associated With Alzheimer’s Disease - Pipeline Insight, 2024 DelveInsight’s, “Dementia Associated With Alzheimer’s Disease - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline la ... Read More
Type 2 Diabetes - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 3,000

Type 2 Diabetes - Pipeline Insight, 2024 DelveInsight’s, “Type 2 Diabetes - Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Type 2 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More
Niemann-Pick disease - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

Niemann-Pick disease - Pipeline Insight, 2024 DelveInsight’s, “Niemann-Pick disease - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann-Pick disease pipeline landscape. It covers the pipeline drug profiles, including clinical and no ... Read More
Cutaneous T-cell lymphoma - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Cutaneous T-cell lymphoma - Pipeline Insight, 2024 DelveInsight’s, “Cutaneous T-cell lymphoma- Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Cutaneous T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including cl ... Read More
Synovial Sarcoma - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Synovial Sarcoma - Pipeline Insight, 2024 DelveInsight’s, “Synovial Sarcoma- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stag ... Read More
Wilson Disease- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Wilson Disease- Pipeline Insight, 2024 DelveInsight’s, “Wilson Disease- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage product ... Read More
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,500

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024 DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the pipeline d ... Read More
Lou Gehrig’s disease - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 3,000

Lou Gehrig’s disease - Pipeline Insight, 2024 DelveInsight’s, “Lou Gehrig’s disease - Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Lou Gehrig’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and non ... Read More
Diabetes - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 5,000

Diabetes - Pipeline Insight, 2024 DelveInsight’s, “Diabetes - Pipeline Insight, 2024” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also c ... Read More
Scars - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

Scars - Pipeline Insight, 2024 DelveInsight’s, “Scars - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the th ... Read More
Myotonic Dystrophy - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Myotonic Dystrophy - Pipeline Insight, 2024 DelveInsight’s, “Myotonic Dystrophy - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 27+ pipeline drugs in Myotonic Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinic ... Read More
HPK1 inhibitors - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

HPK1 inhibitors - Pipeline Insight, 2024 DelveInsight’s, “HPK1 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More
Myositis - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,000

Myositis - Pipeline Insight, 2024 DelveInsight’s, “Myositis - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also co ... Read More
Ischemic Stroke - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 2,500

Ischemic Stroke - Pipeline Insight, 2024 DelveInsight’s, “Ischemic Stroke- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage p ... Read More
B-cell Lymphoma- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 5,000

B-cell Lymphoma- Pipeline Insight, 2024 DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2024” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More
Congenital Adrenal Hyperplasia- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Congenital Adrenal Hyperplasia- Pipeline Insight, 2024 DelveInsight’s, “Congenital Adrenal Hyperplasia- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Congenital Adrenal Hyperplasia pipeline landscape. It covers the pipeline drug profiles, ... Read More
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024 DelveInsight’s, “Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipe ... Read More
Acute Respiratory Distress Syndrome Market Insight, Epidemiology And Market Forecast - 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

Acute Respiratory Distress Syndrome Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights Neonatal fragment crystallizable (Fc) receptor (FcRn), also known as the Brambell receptor, is the major histocompatibility complex (MHC) I-related receptor encoded by the FCGRT gene. In the 19 ... Read More
Alpha-1 Antitrypsin Deficiency Market Insight, Epidemiology and Market Forecast – 2034

Nov 01, 2024 | Published by: DelveInsight | USD 7,950

Alpha-1 Antitrypsin Deficiency Market Insight, Epidemiology and Market Forecast – 2034 Key Highlights According to DelveInsight’s estimates, in 2023, there were approximately 191,589 diagnosed prevalent cases of idiopathic inflammatory myositis in the 7MM. Of these, the United States accounted for 4 ... Read More
Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024 DelveInsight’s, “Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Pseudomonas Aeruginosa Pulmonary In ... Read More
Prostate Cancer - Competitive landscape, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 5,000

Prostate Cancer - Competitive landscape, 2024 DelveInsight’s, “Prostate Cancer - Competitive landscape, 2024,” report provides comprehensive insights about 230+ companies and 265+ drugs in Prostate Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, and route ... Read More
Non‐cystic fibrosis bronchiectasis - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,500

Non‐cystic fibrosis bronchiectasis - Pipeline Insight, 2024 DelveInsight’s, “Non‐cystic fibrosis bronchiectasis - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the pipeline ... Read More
Familial adenomatous polyposis - Pipeline Insight, 2024

Nov 01, 2024 | Published by: DelveInsight | USD 1,250

Familial adenomatous polyposis - Pipeline Insight, 2024 DelveInsight’s, “Familial adenomatous polyposis - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the pipeline drug profiles ... Read More